Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDRT + durvalumab + EP first-line study in extensive-stage small cell lung cancer
ChiCTR2100049490Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, etoposide, cisplatin and carboplatin in small cell lung cancer (SCLC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Median progression-free survival. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
durvalumabetoposidecisplatincarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100049490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049490.